---
title: "Chongqing Genrix Biopharmaceutical Starts Phase III Trial for GR1802 Injection in Urticaria"
date: "2025-02-14 15:49:02"
summary: "Chongqing Genrix Biopharmaceutical initiated phase three clinical trial for its GR1802 injection to target chronic spontaneous urticaria. Chronic spontaneous urticaria is the third indication to enter phase three trials, joining atopic dermatitis and chronic sinusitis with nasal polyps, according to a Friday filing with the Shanghai bourse. Shares of the..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Chongqing Genrix Biopharmaceutical initiated phase three clinical trial for its GR1802 injection to target chronic spontaneous urticaria.

Chronic spontaneous urticaria is the third indication to enter phase three trials, joining atopic dermatitis and chronic sinusitis with nasal polyps, according to a Friday filing with the Shanghai bourse.

Shares of the antibody drug maker closed 4% higher Friday.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250214:G2467925:0/)
